Ads
related to: jazz pharmaceuticals- Careers
Join our Mission to Improve
the Lives of Patients.
- Pipeline
Review our Pipeline and
See How We're Changing Treatment.
- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Careers
Search results
Goldman starts Jazz at buy, cites diversified portfolio (NASDAQ:JAZZ)
Seeking Alpha· 21 hours agoGoldman Sachs initiated coverage of Jazz Pharmaceuticals (JAZZ) with a buy rating, citing its...
Goldman Sachs says buy this biotech stock with more than 60% upside
CNBC· 21 hours agoIt's time for investors to buy the dip on Jazz Pharmaceuticals , according to Goldman Sachs. The...
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial...
WLNS Lansing· 5 days agoJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings, from the Phase ...
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
Zacks via Yahoo Finance· 6 days agoA month has gone by since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have lost...
Here are Wednesday's biggest analyst calls: Apple, Nvidia, Amazon, Meta, Uber, Disney, Coinbase,...
CNBC· 1 day agoHere are Wednesday's biggest calls on Wall Street: BMO initiates Old Dominion as outperform BMO said...
ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision
FierceBiotech· 5 days agoAs zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing
Instacart, Boston Beer upgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 23 hours agoGoldman Sachs initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Buy rating and $169 price...
This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For...
Benzinga· 24 hours agoFor a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Guggenheim analyst Subbu Nambi initiated coverage on Twist ...
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML
MedPage Today· 6 days agoThe STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with...
Stocks making the biggest moves midday: CrowdStrike, GameStop, Dollar Tree, Nvidia and more
CNBC· 20 hours agoCheck out the companies making headlines in midday trading: CrowdStrike — The cybersecurity company...